These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 6088020)

  • 1. Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate.
    Blossey HC; Wander HE; Koebberling J; Nagel GA
    Cancer; 1984 Sep; 54(6 Suppl):1208-15. PubMed ID: 6088020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medroxy-progesterone acetate administration to ovariohysterectomized, oestradiol-primed beagle bitches. Effect on secretion of growth hormone, prolactin and cortisol.
    Rutteman GR; Stolp R; Rijnberk A; Loeffler S; Bakker JA; Bevers MM; Meulenberg PM; Eigenmann JE
    Acta Endocrinol (Copenh); 1987 Feb; 114(2):275-82. PubMed ID: 2950711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenohypophyseal function in bitches treated with medroxyprogesterone acetate.
    Beijerink NJ; Bhatti SF; Okkens AC; Dieleman SJ; Mol JA; Duchateau L; Van Ham LM; Kooistra HS
    Domest Anim Endocrinol; 2007 Feb; 32(2):63-78. PubMed ID: 16455223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ACTH and cortisol plasma levels in cancer patients treated with medroxyprogesterone acetate at high dosages.
    Papaleo C; Carella C; Zito GA; Figlia A; Capuano F; Amato G
    Chemioterapia; 1984 Aug; 3(4):220-2. PubMed ID: 6099752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medroxyprogesterone acetate lowers plasma corticotropin and cortisol but does not suppress anterior pituitary responsiveness to human corticotropin releasing factor.
    Lang I; Zielinski CC; Templ H; Spona J; Geyer G
    Cancer; 1990 Nov; 66(9):1949-53. PubMed ID: 2146010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High dose medroxyprogesteroneacetate in metastasizing breast cancer: correlations between course of the disease and hormone profiles].
    Wander HE; Blossey C; Köbberling J; Nagel GA
    Klin Wochenschr; 1983 Jun; 61(11):553-60. PubMed ID: 6224046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of high-dose medroxyprogesterone acetate on plasma hormone levels and pain relief in patients with advanced prostatic cancer.
    Sasagawa I; Satomi S
    Br J Urol; 1990 Mar; 65(3):278-81. PubMed ID: 1692498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High progesterone receptor concentration in a variant of the ZR-75-1 human breast cancer cell line adapted to growth in oestrogen free conditions.
    van den Berg HW; Martin J; Lynch M
    Br J Cancer; 1990 Apr; 61(4):504-7. PubMed ID: 2139575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis.
    Hellman L; Yoshida K; Zumoff B; Levin J; Kream J; Fukushima DK
    J Clin Endocrinol Metab; 1976 May; 42(5):912-7. PubMed ID: 178684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer.
    Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
    Anticancer Res; 1988; 8(4):647-51. PubMed ID: 2972248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose medroxyprogesterone acetate (MPA) treatment in advanced breast cancer. A review.
    Ganzina F
    Tumori; 1979 Oct; 65(5):563-85. PubMed ID: 390798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High dose medroxyprogesterone acetate in metastatic breast cancer. Comparative clinical, pharmacokinetic and pharmacodynamic data of different forms of administration].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():13-6. PubMed ID: 6215599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
    Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
    Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of contraceptive steroids on hypothalamic-pituitary function.
    Mishell DR; Kletzky OA; Brenner PF; Roy S; Nicoloff J
    Am J Obstet Gynecol; 1977 May; 128(1):60-74. PubMed ID: 403765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Plasma lipoprotein fractions in high-dose medroxyprogesterone acetate therapy in metastatic breast cancer].
    Brockerhoff P; Grill HJ; Holzer A; Kreienberg R; Pollow K; Schicketanz KH; Schwarz V; Rathgen GH
    Gynakol Rundsch; 1991; 31(4):189-200. PubMed ID: 1839014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grwoth hormone, prolactin, and cortisol in dogs developing mammary nodules and an acromegaly-like appearance during treatment with medroxyprogesterone acetate.
    Concannon P; Altszuler N; Hampshire J; Butler WR; Hansel W
    Endocrinology; 1980 Apr; 106(4):1173-7. PubMed ID: 6444575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors].
    Nomura Y; Tashiro H; Hisamatsu K; Toi M
    Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocrine effects of medroxyprogesterone acetate: relation between plasma levels and suppression of adrenal steroids in patients with breast cancer.
    van Veelen H; Willemse PH; Sleijfer DT; Sluiter WJ; Doorenbos H
    Cancer Treat Rep; 1985 Sep; 69(9):977-83. PubMed ID: 3161613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenal suppression by oral high-dose medroxyprogesterone acetate in breast cancer patients.
    van Veelen H; Willemse PH; Sleijfer DT; Pratt JJ; Sluiter WJ; Doorenbos H
    Cancer Chemother Pharmacol; 1984; 12(2):83-6. PubMed ID: 6321047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.